Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Healios KK Ord Shs HLOSF

Healthcare Biotechnology
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.


PINL:HLOSF - Post by User

Healios KK Ord Shs > New PDF
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Comment by Camaronion Aug 04, 2010 1:10pm
327 Views
Post# 17321021

RE: RE: RE: New PDF

RE: RE: RE: New PDF
My reason is that the company has not offered any communication regarding the rationale or potential benefits of the consolidation.

I just received my package today regarding the AGM and voting issues. A mere 16 days before the meeting. Company IR dept shows contempt for shareholder inquiries as per message on answering mahine. All in all feels like something is getting ramrodded though allowing for no to little opportunity for discussion.

If motion is voted down the company can always reserect the issue with an opportunity for shareholder discussion.

Reverse splits typically do not lead to share price appreciation. You have sighted one example (EXP) which currently sits barely above 2X SP after consolidation, not withsatnding the litlle spike after the consolidation which was nowhere near the previous SP spikes. So what really was accomplished that couldn't have been otherwise acomplished with good news an company marketing?

These are just my thoughts. If I assume you are voting in favour, what is your reasoning?

GLTA
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities